Savara Securities Case Nears Lead‑Plaintiff Deadline as Firms Court Investors
Investor attorneys urge eligible shareholders to act by November 7 after the FDA declined to file the MOLBREEVI application for being incomplete.
Overview
- Glancy Prongay & Murray, Faruqi & Faruqi, and other firms are notifying Savara investors of the November 7, 2025 cutoff to seek lead‑plaintiff status.
- The pending suit covers purchasers of Savara securities from March 7, 2024 through May 23, 2025, the period alleged in the complaint.
- The complaint claims Savara misled investors about the completeness of MOLBREEVI’s BLA, expected timelines, and the likelihood of needing additional capital.
- Savara disclosed on May 27 that the FDA issued a refusal‑to‑file citing missing Chemistry, Manufacturing, and Controls information, and the stock fell about 31.7% that day to $1.94.
- A Guggenheim report that day lowered its price target and warned of commercialization delays, while firms invite tips from whistleblowers and former employees.